HTC
WST icon

Haverford Trust Company’s West Pharmaceutical WST Stock Holding History

Haverford Trust Company’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-767
Closed -$251K – 399
2024
Q4 		$251K Sell
767
-94
-11% -$29.6K ﹤0.01% 359
2024
Q3 		$258K Buy
861
+73
+9% +$22.4K ﹤0.01% 375
2024
Q2 		$260K Buy
788
+102
+15% +$36K ﹤0.01% 370
2024
Q1 		$271K Hold
686
– – ﹤0.01% 346
2023
Q4 		$242K Sell
686
-45
-6% -$15.9K ﹤0.01% 341
2023
Q3 		$274K Buy
+731
New +$283K ﹤0.01% 323
2022
Q2 		– Sell
-2,357
Closed -$968K – 363
2022
Q1 		$968K Hold
2,357
– – 0.01% 199
2021
Q4 		$1.1M Hold
2,357
– – 0.01% 194
2021
Q3 		$1M Hold
2,357
– – 0.01% 199
2021
Q2 		$846K Buy
+2,357
New +$779K 0.01% 211

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Haverford Trust Company's WST Position: Q1 2025 in Review

Haverford Trust Company sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 767 shares — an estimated $251K sold.

Haverford Trust Company first reported a position in WST in Q2 2021 and held it in 10 quarters. The position peaked at $1.1M in Q4 2021. 715 funds tracked by Wall St. Rank hold WST as of Q1 2025.

  • Haverford Trust Company reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Haverford Trust Company sold 767 West Pharmaceutical shares in Q1 2025, an estimated $251K.
  • Haverford Trust Company first reported a position in West Pharmaceutical in Q2 2021 and held it in 10 quarters.
  • Haverford Trust Company's West Pharmaceutical position peaked at $1.1M in Q4 2021.
  • 715 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Haverford Trust Company's 13F filing for Q1 2025, filed 14 May 2025.